18 studies found for:    "Leber hereditary optic neuropathy" OR "Hereditary Optic Atrophy"
Show Display Options
RSS Create an RSS feed from your search for:
"Leber hereditary optic neuropathy" OR "Hereditary Optic Atrophy"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
Condition: Leber Hereditary Optic Neuropathy
Intervention: Drug: rAAV2-ND4
2 Completed Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
3 No longer available Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Condition: Leber's Hereditary Optic Neuropathy
Intervention: Drug: EPI-743
4 Terminated
Has Results
Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Device: Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
5 Active, not recruiting Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
Condition: Leber Hereditary Optic Neuropathy
Intervention: Genetic: GS010
6 Recruiting Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: injection of scAAV2-P1ND4v2 5.00x10e9 vg (Low),;   Drug: injection of scAAV2-P1ND4v2 2.46X10e10 vg (Med);   Drug: injection of scAAV2-P1ND4v2 1.0X10e11vg (High)
7 Recruiting A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: elamipretide (MTP-131) 1% topical ophthalmic solution;   Drug: Vehicle topical ophthalmic solution
8 Completed RHODOS Follow-up Single-visit Study
Condition: Leber's Hereditary Optic Neuropathy
Intervention:
9 Completed Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
Condition: Leber Hereditary Optic Neuropathy (LHON)
Intervention:
10 Unknown  Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
Condition: Leber Hereditary Optic Neuropathy
Intervention: Drug: cyclosporine
11 Withdrawn Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
12 Not yet recruiting Post Authorisation Safety Study With Raxone in LHON Patients
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Drug: Idebenone
13 Not yet recruiting Study to Assess the Efficacy and Safety of Raxone in LHON Patients
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Drug: Idebenone
14 Completed A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
Condition: Optic Atrophy, Hereditary, Leber
Intervention: Drug: curcumin
15 Recruiting Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation
Condition: Optic, Atrophy, Hereditary, Leber
Interventions: Genetic: GS010;   Other: Sham Intravitreal Injection
16 Recruiting Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
Condition: Optic, Atrophy, Hereditary, Leber
Interventions: Genetic: GS010;   Other: Sham Intravitreal Injection
17 Completed Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
Conditions: Optic Atrophy;   Non-arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses
18 Enrolling by invitation Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease
Condition: Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)

Indicates status has not been verified in more than two years